EP2260037A2 - Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine - Google Patents

Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine

Info

Publication number
EP2260037A2
EP2260037A2 EP09709821A EP09709821A EP2260037A2 EP 2260037 A2 EP2260037 A2 EP 2260037A2 EP 09709821 A EP09709821 A EP 09709821A EP 09709821 A EP09709821 A EP 09709821A EP 2260037 A2 EP2260037 A2 EP 2260037A2
Authority
EP
European Patent Office
Prior art keywords
varenicline base
varenicline
base
polymorphic form
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09709821A
Other languages
German (de)
English (en)
Inventor
Stephen Benedict David Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medichem SA
Original Assignee
Medichem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medichem SA filed Critical Medichem SA
Publication of EP2260037A2 publication Critical patent/EP2260037A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Definitions

  • the present invention relates to a novel crystalline form of varenicline base, i.e. a hydrate of varenicline base, designated herein as Form II, and to a method for obtaining and preparing the same.
  • Varenicline (Compound I) is the international commonly accepted name for 7, 8, 9, 10-tetrahydro-6, 10- methano-6H-pyrazino [2 , 3-h] [3] benzazepine (which is also known as 5, 8, 14-triazatetracyclo [ 10.3.1. O 2 ' 11 . O 4 ' 9 ] - hexadeca-2 (11) , 3, 5, 7, 9-pentaene) , and has an empirical formula of C13H13N3 and a molecular weight of 211.26.
  • varenicline L-tartrate The L-tartrate salt of varenicline has been selected for medical purpose and is commercially marketed for the treatment of smoking addiction.
  • Varenicline L-tartrate is a partial agonist selective for ⁇ 4 ⁇ 2 nicotinic acetylcholine receptor subtypes.
  • varenicline L-tartrate is marketed under the name ChantixTM, and is indicated as an aid to smoking cessation treatment.
  • Varenicline base and its pharmaceutically acceptable acid addition salts are described in U.S. Patent No. 6,410,550.
  • Example 26 of U.S. Patent No. 6,410,550 describes the preparation of varenicline base, which is subsequently converted into its hydrochloride salt.
  • varenicline base is isolated from a dichloromethane solution to afford the compound as a light yellow oil which solidified upon standing to give a solid.
  • U.S. Patent No. 6,410,550 only reports the melting point of this solid (138-140 0 C), and does not provide the crystalline data of said compound. Namely, there is no crystal structure data in the literature regarding varenicline base. In our hands, the varenicline base polymorphic form obtained in U.S. Patent No. 6,410,550 has been isolated and characterized as an anhydrous crystalline solid, and has been denominated herein as Form I . International publication No. WO 2008/060487 describes that anhydrous varenicline base shows polymorphism. More precisely, four different crystalline forms of varenicline base are provided in this reference (designated therein as Forms A, C, D, and E) . Polymorphism is very common among pharmaceutical substances.
  • varenicline base It is commonly defined as the ability of any substance to exist in two or more crystalline phases that have a different arrangement and/or conformation of the molecules in the crystal lattice. Different polymorphs differ in their physical properties such as melting point, solubility, chemical reactivity, etc. These properties may appreciably influence pharmaceutical properties such as dissolution rate and bioavailability.
  • identifying and isolating new polymorphic forms of varenicline base that may have superior chemical and/or physical properties. Further, it would be desirable to have reliable processes for producing varenicline base in one or more of its new polymorphic forms. Additionally, the new polymorphic forms of varenicline base could be used to prepare improved pharmaceutical compositions .
  • the invention relates generally to a crystalline polymorphic form of 7, 8, 9, 10-tetrahydro-6, 10-methano-6H- pyrazino [2, 3-h] [3] benzazepine, varenicline base, i.e. a hydrate of varenicline base, designated herein as Form II, and to a method for preparing and obtaining the same .
  • varenicline base i.e. a hydrate of varenicline base, designated herein as Form II
  • Figure 1 illustrates the X-ray powder diffractogram (XRD) of varenicline base Form I obtained in Example 1.
  • FIG. 1 illustrates the Infrared (IR) spectrum of varenicline base Form I obtained in Example 1.
  • Figure 3 illustrates the Differential Scanning Calorimetry (DSC) thermogram in an open pan of varenicline base Form I obtained in Example 1.
  • Figure 4 illustrates the X-ray powder diffractogram (XRD) of varenicline base Form II, i.e. a hydrate of varenicline base, obtained in Example 2.
  • XRD X-ray powder diffractogram
  • Figure 5 illustrates the Infrared (IR) spectrum of varenicline base Form II, i.e. a hydrate of varenicline base, obtained in Example 2.
  • Figure 6 illustrates the X-ray powder diffractogram (XRD) of varenicline base mixture of Form I and Form II obtained in Example 3.
  • IR Infrared
  • XRD X-ray powder diffractogram
  • varenicline base can exist in a new crystalline form, i.e. a hydrate of varenicline base.
  • This new form of varenicline base has been prepared and characterized as described herein and is referred to herein as Form II.
  • our inventors have isolated anhydrous crystalline solid varenicline base from a dichloromethane solution.
  • the obtained crystalline polymorphic form of varenicline base (i.e. prior art varenicline base) has been designated herein as Form I.
  • Varenicline base polymorphic Form I has been characterized herein by X-ray powder diffraction (XRD) , Infrared spectrometry (IR), and Differential Scanning Calorimetry (DSC) (see Figures 1, 2, and 3, respectively) .
  • XRD X-ray powder diffraction
  • IR Infrared spectrometry
  • DSC Differential Scanning Calorimetry
  • a first aspect of the present invention includes varenicline base polymorphic Form II characterized by its X-ray powder diffraction pattern (XRD) .
  • Figure 4 illustrates the XRD (2 ⁇ ) ( ⁇ 0.2°) of varenicline base polymorphic Form II which has its main peaks at approximately 8.8, 9.3, 10.7, 12.0, 13.8, 14.4, 16.2, 17.2, 17.8, 18.6, 20.0, 20.7, 20.8, 21.2, 26.9 and 27.8° with further peaks at 15.6, 19.0, 21.6, 22.8, 28.4 and 28.9° .
  • varenicline base polymorphic Form II has been characterized by Infrared (IR) spectrum.
  • Figure 5 illustrates the IR spectrum of varenicline base polymorphic Form II.
  • Another aspect of the present invention is to provide a process for preparing varenicline base Form II, said process comprising (i) dissolving varenicline base in a selected solvent comprising water, to obtain a solution, and (ii) removing the solvent from said solution, to give varenicline base Form II.
  • the selected solvent comprising water preferably is water.
  • the step (ii) of removing the solvent from said solution is carried out by evaporating the solvent.
  • the step (ii) of removing the solvent from said solution is carried out by leaving the product to precipitate to obtain a suspension, and filtering the suspension.
  • the varenicline base used for preparing varenicline base Form II can be either varenicline base obtained by a known method.
  • varenicline base polymorphic Form II of the invention is a hydrate of varenicline base .
  • Another aspect of the invention includes a hydrate of varenicline base.
  • the hydrate of varenicline base of the invention shows a loss on drying of about 4.8% on heating between about 85° and 115 0 C, as determined by Thermal Gravimetric Analysis (TGA) .
  • Another aspect of the invention includes the use of varenicline base crystalline Form II, i.e. a hydrate of varenicline base, for preparing varenicline base polymorphic Form I, i.e. anhydrous varenicline base.
  • the invention includes a process for preparing varenicline base polymorphic Form I, said process comprising removing the water from varenicline base Form II by means of azeotropic distillation.
  • the invention includes a process for preparing varenicline base polymorphic Form I, said process comprising removing the water from varenicline base Form II by means of heat- drying said varenicline base Form II.
  • the heat-drying can be carried out under reduced pressure.
  • the present invention also relates to mixtures of varenicline base Form I and Form II.
  • the inventors have found that by dissolving varenicline base in a solvent comprising water and ethanol and removing the solvent, varenicline base mixture of Form I and Form II is obtained (see Example 3) .
  • Another aspect of the invention includes the use of varenicline base crystalline Form II for preparing and obtaining pharmaceutically acceptable salts of varenicline .
  • Another aspect of the invention includes the use of varenicline base crystalline Form II for preparing and obtaining varenicline L-tartrate.
  • DSC measurement was performed in vented pan at a scan rate of 10° C/minute from 25.0° C to 270.0° C under a nitrogen purge with a DSC823 available from Mettler- Toledo.
  • Varenicline base (100 mg) was dissolved in water (0.5 mL) and heated to 70 0 C for one hour. The solution was allowed to cool to room temperature, and stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature conditions) .
  • Example 3 Preparation of a mixture of varenicline base Form I and Form II
  • Varenicline base (100 mg) was dissolved in a 20:80 mixture of water and ethanol (0.5 mL) and heated to 70 0 C for one hour. The solution was allowed to cool to room temperature, and stirred for 24 hours at this temperature before evaporation of the solvent (by opening the vial and allowing to evaporate under ambient temperature conditions) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention porte d'une manière générale sur une forme polymorphe cristalline de 7, 8, 9, 10-tétrahydro-6, 10-méthano-6H-pyrazino[2,3-h][3]benzazépine, la varénicline base, à savoir un hydrate de varénicline base, appelée ici Forme II, ainsi que sur un procédé pour préparer et obtenir celle-ci.
EP09709821A 2008-02-15 2009-02-13 Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine Withdrawn EP2260037A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6603208P 2008-02-15 2008-02-15
PCT/EP2009/051727 WO2009101185A2 (fr) 2008-02-15 2009-02-13 Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine

Publications (1)

Publication Number Publication Date
EP2260037A2 true EP2260037A2 (fr) 2010-12-15

Family

ID=40852121

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09709821A Withdrawn EP2260037A2 (fr) 2008-02-15 2009-02-13 Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine

Country Status (2)

Country Link
EP (1) EP2260037A2 (fr)
WO (1) WO2009101185A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (fr) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Comprimé de varénicline et son procédé de fabrication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1044189T4 (en) * 1997-12-31 2015-03-30 Pfizer Prod Inc Aryl-fused fused azapolycyclic connections
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
DE60225433T2 (de) * 2001-04-20 2008-06-12 Pfizer Products Inc., Groton Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009101185A2 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
US11717524B1 (en) 2022-03-11 2023-08-08 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (fr) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Comprimé de varénicline et son procédé de fabrication
US11779587B2 (en) 2022-03-11 2023-10-10 Par Pharmaceutical, Inc. Vareniciline compound and process of manufacture thereof
US11872234B2 (en) 2022-03-11 2024-01-16 Par Pharmaceutical, Inc. Vareniciline compound and process of manufacture thereof

Also Published As

Publication number Publication date
WO2009101185A2 (fr) 2009-08-20
WO2009101185A3 (fr) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2017008773A1 (fr) Formes cristallines d'acide obéticholique
EP2502917A1 (fr) Formes cristallines à l'état solide de 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
US8440825B2 (en) Fumaric acid salt of varenicline
WO2007109799A2 (fr) Polymorphes de malate d'eszopiclone
WO2016131431A1 (fr) Formes solides d'empagliflozine
WO2014121901A1 (fr) Formes polymorphes
EP2342195B1 (fr) Formes cristallines d un sel de malate de 2-indolinone à substitution 3-pyrrole
US8389562B2 (en) Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP1641741A1 (fr) Polymorphe b du chlorhydrate de levalbuterol
KR20160045068A (ko) 리팍시민 κ 제조공정
EP3784675A1 (fr) Formes à l'état solide de lorlatinib et préparation associée
EP2276722A2 (fr) Forme polymorphe d un dérivé de mésylate d amino-indane
EP2260037A2 (fr) Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine
CA2814357C (fr) Hydrate de tartrate de 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoropiperidin-2-one
JP7152122B2 (ja) エダラボン塩
WO2017125504A1 (fr) Formes polymorphes de tert-butanolate de bromhydrate de vortioxétine
WO2017036884A1 (fr) Co-cristal de lésinurad, forme libre/ester éthylique de lésinurad
EP2189461B1 (fr) Hydrochlorure crystalline d'irinotecan et procédés pour sa préparation
US20080146805A1 (en) Process for the Production of Levorphanol and Related Compounds
WO2008038143A2 (fr) Nouvelles formes solides du rimonabant et procédés de synthèse pour la préparation de celles-ci
WO2015170340A2 (fr) Nouveaux polymorphes de chlorhydrate de sitagliptine, procédés de préparation et composition pharmaceutique de ceux-ci
US10927121B1 (en) Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
US8779005B2 (en) Salts of desvenlafaxine and a method of their preparation
CN116041323A (zh) Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用
CN103113348A (zh) 枸地氯雷他定的假多晶型及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17P Request for examination filed

Effective date: 20100914

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

18W Application withdrawn

Effective date: 20101104

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WINTER, STEPHEN, BENEDICT, DAVID

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WINTER, STEPHEN, BENEDICT, DAVID